How should you take entrectinib/Luo Shengquan?

Entrectinib (Entrectinib) is an oral targeted drug, suitable for ROS1-positive non-small cell lung cancer , NTRK fusion-driven solid tumors and some ALK-positive cases. The usual adult dose is 600 mg orally daily until disease progression or unacceptable adverse effects. This dosage design facilitates long-term continuous treatment and can be individually adjusted according to the patient's tolerance and blood drug concentration.

For patients with solid tumors, the adult dose is also 600 mg once daily.For pediatric patients, the dose is adjusted based on body surface area (BSA). For example, 250mg/m² is recommended once a day for infants and young children between 1 month and 6 months old; for children over 6 months old, the daily dose is calculated based on the body surface area to ensure that the drug reaches a safe and effective blood concentration in the body. For adults with body surface area ≥1.5 m², the recommended dose is 600 mg once daily, which is consistent with the dose for adults with non-small cell lung cancer.

The oral route of entrectinib is simple, but attention should be paid to the effects of taking it on an empty stomach or with food, as well as possible adverse reactions, including fatigue, nausea, blood pressure changes, and neurological symptoms. Patients need regular follow-up and laboratory examinations during medication, including liver function, renal function and hematological indicators, in order to detect and manage adverse reactions in a timely manner while ensuring drug efficacy.

Pediatric patients especially require physician assessment of body surface area and weight to ensure safe dosing and consistent efficacy. The course of drug treatment generally continues until disease progression or intolerable toxicity occurs, and it is not recommended to discontinue the drug on your own or adjust the dose without authorization. Professional follow-up and regular monitoring are key to ensuring the long-term therapeutic effect of entrectinib.

In general, entrectinib has clear indications and standardized dosage regimens, and both adult and pediatric patients can be treated according to body surface area and target conditions. Through standardized medication and scientific follow-up, entrectinib can achieve long-term disease control in patients with positive ROS1 or NTRK fusions, providing a reliable guarantee for tumor treatment.

Reference materials:https://www.roche.com/products/rozlytrek